



**Select
Health**

Select Health Medical Policies

Infectious Disease Policies

Table of Contents

Policy Title	Policy Number	Last Reviewed
Fecal Microbiota Therapy	522	12/03/23



FECAL MICROBIOTA THERAPY

Policy # 522

Implementation Date: 1/29/13

Review Dates: 2/20/14, 3/19/15, 2/11/16, 12/21/17, 12/13/18, 12/17/20, 12/3/21, 11/13/22, 12/3/23

Revision Dates: 11/29/16, 1/23/17, 10/19/22, 11/18/22

Disclaimer:
 1. Policies are subject to change without notice.
 2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Clostridium difficile (C diff) is a bacterial infection that results in millions of human infections worldwide annually. The most common clinical presentation of *Clostridium difficile*-Associated Infection (CDI) is mild-to-moderate diarrhea, with some patients having mucus or blood in stool. Manifestations of *C. difficile*-associated diarrhea with colitis, include watery diarrhea with lower abdominal pain and cramping, low grade fever, and leukocytosis. *C. difficile* illness often develops during or shortly after a course of antibiotics. But signs and symptoms may not appear for weeks or months afterward.

The Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America define mild, moderate, severe, and complicated *C. diff* as follows:

Clinical Definition	Supportive Clinical Data
Initial episode, mild or moderate	Leukocytosis with a white blood cell count of 15,000 cells/ μ L or lower and a serum creatinine level less than 1.5 times the premorbid level
Initial episode, severe	Leukocytosis with a white blood cell count of 15,000 cells/ μ L or higher and a serum creatinine level greater than 1.5 times the premorbid level
Initial episode, severe, complicated	Hypotension or shock, ileus, megacolon

C. difficile infection is usually treated with antibiotic therapy, though relapses may occur. The most common antibiotics used are metronidazole and vancomycin. Most recently, fidaxomicin (Dificid) has gained FDA approval for treatment of CDI. Though these agents are effective, increasing resistance by *C. difficile* has emerged, which has led to an increasing number of antibiotic failures.

Fecal microbiota therapy, also called fecal biotherapy, fecal bacteriotherapy, fecal microbiota transplantation, fecal flora reconstitution, fecal transfer, or stool transplantation, was first described in 1958 as a successful treatment for antibiotic-induced diarrhea in patients who did not respond to other treatments and whose critical condition continued to worsen. Since then, fecal microbiota therapy has continued to be used rarely in the United States and sporadically in other countries, mostly due to aesthetic issues, patient acceptance, and some concerns about disease transmission. Interest in this procedure has grown substantially over the past few years due to the increasing incidence and severity of *C. difficile* infection (CDI), as well as the increasing resistance of CDI to current care antibiotic therapy. Fecal microbiota therapy involves the reintroduction of healthy fecal bacteria from a donor into the GI tract of a patient diagnosed with CDI. There have been successful results, defined as clearance of diarrhea or negative *C. difficile* toxin assays, with fecal microbiota transplantation (FMT) administered to the proximal colon *via* colonoscope, enema, or upper GI tract *via* nasoduodenal (ND) tube, or even orally in the case of the newer frozen capsule formulations. Regardless of the delivery method chosen, the initial steps in the procedure are similar: evaluating patient eligibility, patient consent, determining and screening



donors, and in most cases, discontinuing the recipient's antibiotics prior to the procedure. The exact preparation and volume of the donated sample and location of delivery can vary.

Clinicians often elect to utilize stool donations from individuals living in the same household, hypothesizing that in close living arrangements—and particularly with intimate partners—potential pathogens would likely already have been widely shared by both parties. Donation from an intimate partner diminishes the risk of transferring an additional infectious agent (to which the recipient has not been previously exposed) into their GI tract. Regardless of the relationship of the recipient and donor, rigorous screening for other infectious agents is recommended.

As this therapy has evolved, attempts at developing standardized commercial preparations of fecal material for transplantation have also evolved. There remain no FDA-approved commercial therapies. One nonprofit stool bank that sells frozen fecal matter in capsule form (Capsule G3) or frozen solutions is called OpenBiome (Somerville, MA). It provides frozen stool preparations in 250 cc frozen solution (Lower Delivery Microbiota Preparation-FMP250) for colonoscopic delivery, 30 cc frozen solution (Upper Delivery Microbiota Preparation-FMP30), and the frozen capsules. The capsules contain concentrated formulations of the same screened and processed microbiota preparations as OpenBiome's other FMT treatments. The recommended number of capsules for treatment of CDI is 30 capsules, swallowed consecutively in a single session. Capsules are size 00, approximately the size of a large multivitamin. OpenBiome provides 2 'placebo' test capsules with each treatment. The patient may be asked to ingest one test capsule prior to the start of treatment, under direct observation of the physician, to ensure the patient's ability to swallow and mitigate the risks associated with aspiration. Regardless of the formulation used, it is kept frozen until time of administration and then warmed to room temperature. The materials are administered in the same fashion as other fresh stool preparations. The stool undergoes extensive preparation including testing for several pathogens. The donors also undergo testing for potentially transmittable conditions. The material has a shelf-life of approximately 6 months when in the frozen state.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

SelectHealth covers fecal microbiota therapy as a proven therapy for members with *Clostridium difficile* infection (CDI) *in limited circumstances*.

SelectHealth covers OpenBiome capsules/commercially prepared fecal concentrate as a proven therapy for members with *Clostridium difficile* infection (CDI) in the same circumstances as fresh stool specimen transplantation.

Recommended Criteria for Coverage:

1. For mild-to-moderate CDI:
 - a. Patient has positive *C. difficile* PCR or toxin assay, **and**
 - b. At least three previous episodes of CDI, and have presented with a fourth episode
2. Fulminant CDI: (formerly referred to as severe CDI), as defined by hypotension or shock, ileus, or megacolon (must meet either a or b)
 - a. Recurrent infection that is fulminant; **or**
 - b. Patient is not improving after three days of antibiotic therapy

SelectHealth does not cover fecal microbiota therapy for any other indication; use in other settings is considered investigational.

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

A technology assessment completed on January 29, 2013, identified six systematic reviews and sixteen peer-reviewed journal articles regarding fecal microbiota therapy which met inclusion criteria for review. These studies involved 391 patients with recurrent or recalcitrant *C. difficile* infections. The largest study was only 70 patients (Mattila et al.). The severity of the diarrheal disease varied in the studies from mild-to-moderate to severe. All studies involved patients with recurrent or recalcitrant disease who had failed multiple courses of antibiotic therapy. The response rate in these studies ranged from 73.3% to 100%. The lowest outcomes tended to be noted for therapies administered via nasogastric tube (i.e., 73.3% and 83.0%). The mean response rate for all studies was 92.5%.

Study duration impacted the ability to determine the durability of the therapy as many studies were of 3 months duration or less. However, Brandt et al. identified a durability of effect extending out to 17 months, and Rohlke et al. identified effectiveness of the therapy to 27.7 months. It was remarkable to note the resolution of the diarrhea occurred in as little as 1-day post-instillation of the microbiota therapy (Kelly et al. and Yoon et al.), but often in 2–3 days (Garborg et al. and Brandt et al.).

Most studies suffered from methodological limitations due to the lack of blinding, or randomization, though either would be difficult to achieve for this therapy. Despite the variability in treatment protocols and patient populations, the available published literature demonstrates fecal microbiota therapy to have high efficacy in the resolution of *C. difficile* induced disease commensurate with treatment following standard regimens of metronidazole and vancomycin (i.e., resolution of diarrhea > 90% in all patient cohorts).

Most patients in whom fecal microbiota therapy was not efficacious in eliminating symptoms associated with *C. diff* were immunocompromised, elderly, or had significant secondary illness. In patients who failed conservative treatment, fecal transplantation appears to be a viable last option having good outcomes and a low risk profile as no significant adverse events were reported in the literature.

With regards to commercially prepared frozen stool preparation, four systematic reviews and 4 primary studies were identified for use in the management of fecal microbiota therapy during a review completed in November of 2016. Though the studies were of small size and had some methodological issues, the outcomes demonstrated non-inferior outcomes and adverse events compared to fresh FMT. Follow-up times after therapy ranged from 13 weeks to 6 months.

Billing/Coding Information

CPT CODES

- | | |
|--------------|--|
| 0780T | Instillation of fecal microbiota suspension via rectal enema into lower gastrointestinal tract |
| 44705 | Preparation of fecal microbiota for instillation, including assessment of donor specimen |

HCPCS Codes

G0455	Preparation with instillation of fecal microbiota by any method, including assessment of donor specimen
J3490	Unclassified drugs
J3590	Unclassified biologics

Key References

1. Aas, J., C.E. Gessert, and J.S. Bakken, Recurrent *Clostridium difficile* colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. *Clin Infect Dis*, 2003. 36(5): p. 580-5.
2. Bartlett, J.G., Clinical practice. Antibiotic-associated diarrhea. *N Engl J Med*, 2002. 346(5): p. 334-9.
3. Brandt, L.J., et al., Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent *Clostridium difficile* infection. *Am J Gastroenterol*, 2012. 107(7): p. 1079-87.
4. Canadian Agency for Drugs and Technologies in Health. Fecal Microbiota Transplantation (Fecal Transplant) for Adults With Inflammatory Bowel Disease. 2015 October 2015 [cited 2016 October 16]; Available from: <https://www.cadth.ca/dv/fecal-microbiota-transplantation-fecal-transplant-adults-inflammatory-bowel-disease>.
5. Clinic. *M. C. difficile*. 2013 November 3, 2010 [cited 2013 January 4]; Available from: <http://www.mayoclinic.com/health/c-difficile/DS00736/DSECTION=symptoms>.
6. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) *Clinical Infectious Diseases*® 2018;66(7):e1–e48
7. Cohen, S.H., et al., Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol*, 2010. 31(5): p. 431-55.
8. European consensus conference on faecal microbiota transplantation in clinical practice *Gut* 2017;66:569–580. doi:10.1136/gutjnl-2016-313017
9. Florea, N.R., et al., Treatment of *Clostridium difficile*-associated disease (CDAD). *Conn Med*, 2003. 67(3): p. 153-5.
10. Garborg, K., et al., Results of faecal donor instillation therapy for recurrent *Clostridium difficile*-associated diarrhoea. *Scand J Infect Dis*, 2010. 42(11-12): p. 857-61.
11. Grehan, M.J., et al., Durable alteration of the colonic microbiota by the administration of donor fecal flora. *J Clin Gastroenterol*, 2010. 44(8): p. 551-61.
12. Guidelines for Diagnosis, Treatment, and Prevention of *Clostridium difficile* Infections *Am J Gastroenterol* 2013; 108:478–498; doi: 10.1038/ajg.2013.
13. Hamilton, M.J., et al., Standardized frozen preparation for transplantation of fecal microbiota for recurrent *Clostridium difficile* infection. *Am J Gastroenterol*, 2012. 107(5): p. 761-7.
14. Kassam, Z., et al., Fecal transplant via retention enema for refractory or recurrent *Clostridium difficile* infection. *Arch Intern Med*, 2012. 172(2): p. 191-3.
15. Kelly, C.P., C. Pothoulakis, and J.T. LaMont, *Clostridium difficile* colitis. *N Engl J Med*, 1994. 330(4): p. 257-62.
16. Kelly, C.R., L. de Leon, and N. Jasutkar, Fecal microbiota transplantation for relapsing *Clostridium difficile* infection in 26 patients: methodology and results. *J Clin Gastroenterol*, 2012. 46(2): p. 145-9.
17. Kyne, L., et al., Asymptomatic carriage of *Clostridium difficile* and serum levels of IgG antibody against toxin A. *N Engl J Med*, 2000. 342(6): p. 390-7.
18. LaMont, J.T. Clinical manifestations and diagnosis of *Clostridium difficile* infection in adults. 2012 June 11, 2012 [cited 2013 January 4]; Available from: http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-clostridium-difficile-infection-in-adults?source=search_result&search=c+diff&selectedTitle=2~150.
19. Lee, C.H., et al., Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent *Clostridium difficile* Infection: A Randomized Clinical Trial. *JAMA*, 2016. 315(2): p. 142-9.
20. MacConnachie, A.A., et al., Faecal transplant for recurrent *Clostridium difficile*-associated diarrhoea: a UK case series. *QJM*, 2009. 102(11): p. 781-4.
21. Malani, P.N. and K. Rao, Expanded Evidence for Frozen Fecal Microbiota Transplantation for *Clostridium difficile* Infection: A Fresh Take. *JAMA*, 2016. 315(2): p. 137-8.
22. Mattila, E., et al., Fecal transplantation, through colonoscopy, is effective therapy for recurrent *Clostridium difficile* infection. *Gastroenterology*, 2012. 142(3): p. 490-6.
23. McFarland, L.V., et al., Nosocomial acquisition of *Clostridium difficile* infection. *N Engl J Med*, 1989. 320(4): p. 204-10.
24. McFee, R.B. *Clostridium difficile*. 2009 [cited 2013 January 4]; Available from: <http://www.mdconsult.com/das/article/body/393695522-3/jorg=journal&source=&sp=22258072&sid=0/N/702739/1.html?issn=0011-5029#S0011502909000650>.
25. Mellow, M.H. and A. Kanatzar, Colonoscopic fecal bacteriotherapy in the treatment of recurrent *Clostridium difficile* infection—results and follow-up. *J Okla State Med Assoc*, 2011. 104(3): p. 89-91.
26. Openbiome. FMT Capsule G3. 2016 [cited 2016 October 27]; Available from: <http://www.openbiome.org/fmtcapsules>.
27. Rao, K. and V.B. Young, Fecal microbiota transplantation for the management of *Clostridium difficile* infection. *Infect Dis Clin North Am*, 2015. 29(1): p. 109-22.
28. Riggs, M.M., et al., Asymptomatic carriers are a potential source for transmission of epidemic and non-epidemic *Clostridium difficile* strains among long-term care facility residents. *Clin Infect Dis*, 2007. 45(8): p. 992-8.
29. Rohlke, F., C.M. Surawicz, and N. Stollman, Fecal flora reconstitution for recurrent *Clostridium difficile* infection: results and methodology. *J Clin Gastroenterol*, 2010. 44(8): p. 567-70.

Fecal Microbiota Therapy, continued

30. Rohlke, F. and N. Stollman, Fecal microbiota transplantation in relapsing *Clostridium difficile* infection. *Therap Adv Gastroenterol*, 2012. 5(6): p. 403-20.
31. Rossen, N.G., et al., Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. *World J Gastroenterol*, 2015. 21(17): p. 5359-71.
32. Schroeder, M.S., *Clostridium difficile*-associated diarrhea. *Am Fam Physician*, 2005. 71(5): p. 921-8.
33. Silverman, M.S., I. Davis, and D.R. Pillai, Success of self-administered home fecal transplantation for chronic *Clostridium difficile* infection. *Clin Gastroenterol Hepatol*, 2010. 8(5): p. 471-3.
34. The use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridium difficile* infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. *Journal of Hospital Infection* 100 (2018) S1eS31
35. van Nood, E., et al., Duodenal Infusion of Donor Feces for Recurrent *Clostridium difficile*. *New England Journal of Medicine*, 2013. 0(0): p. null.
36. Wang, S., et al., Systematic Review: Adverse Events of Fecal Microbiota Transplantation. *PLoS One*, 2016. 11(8): p. e0161174.
37. Wensich, C., et al., Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of *Clostridium difficile*-associated diarrhea. *Clin Infect Dis*, 1996. 22(5): p. 813-8.
38. Yoon, S.S. and L.J. Brandt, Treatment of refractory/recurrent *C. difficile*-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. *J Clin Gastroenterol*, 2010. 44(8): p. 562-6.
39. Youngster, I., et al., Oral, capsulized, frozen fecal microbiota transplantation for relapsing *Clostridium difficile* infection. *JAMA*, 2014. 312(17): p. 1772-8.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association